Labrador Won't Stop Staring at Sibling Having Laser, Vet Has a Plan
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Internet users can't cope with a Labrador wearing "doggles" because he couldn't be trusted not to stare directly at the laser.
Simba, an 11-year-old Labrador, is undergoing physiotherapy at Modern Vet in Dubai to treat his severe arthritis. Megan Taylor, the veterinary physiotherapist on his case , told Newsweek that laser therapy helps "reduce pain and inflammation" by using light energy. This in turn can boost the blood flow, speed up healing, and helps ease discomfort in stiff joints.
"It's a quick and pain free procedure, most dogs will feel relaxed during it and may fall asleep," Taylor, 31, said.
Thankfully for Simba, he is often joined by his canine sibling, Daboa, who likes to attend the appointments and offer "moral support."
Simba receiving laser treatment, and Daboa wearing protective goggles.
Simba receiving laser treatment, and Daboa wearing protective goggles.
@tayloredvetphysio / TikTok
There's just one slight problem with that, because Daboa cannot be trusted not to stare directly at the harmful laser. It's all just so fun and exciting to Daboa, also a Labrador, so Taylor had to come up with a solution to protect his eyes.
While Simba was lying on the floor receiving the laser treatment, Dabao was given a pair of so-called "doggles" to wear.
Taylor continued: "The laser uses a light that can be damaging to your eyes, so myself and his owner are also wearing goggles. The owners knew Dabao would not sit still and would be looking at the light, so we put goggles on him too.
"The owners and I laughed so much when we saw Daboa sitting there wagging his tail, happily, in his glasses. Some dogs don't like the glasses or tolerate them well, but he wasn't fazed at all."
Indeed, Taylor explained that it's not uncommon for owners to take their other pets to appointments in order to provide company and support. Daboa certainly did a great job at that.
Taylor couldn't resist capturing a clip of Daboa looking so excited about his new accessory. The video of him wearing his protective eyewear was shared on TikTok (@tayloredvetphysio) and it's gone viral with more than 1.3 million views and over 131,000 likes at the time of writing.
Needless to say, internet users can't get enough of Daboa wearing his goggles with pride. In just a matter of days, the viral video has generated over 140 comments on TikTok as social media users lauded Daboa's brotherly support.
One comment reads: "Under those goggles I know his eyes are open and trying to find that light."
Another person replied: "He said I don't know what's going on but I'm having fun."
Another TikTok user joked: "Dog: 'Dad, do we get to keep the goggles?'"
While one commenter wrote: "I just love everything about this and it gave me a big smile."
Taylor has loved the overwhelmingly positive reaction to the video, and she's laughed so much at the hilarious comments. But most importantly, she's thankful to be able to help Simba live a joyful and fulfilling life.
"Simba is able to walk again and much more comfortable with the physiotherapy sessions and Daboa is as goofy and happy as ever," Taylor told Newsweek.
Do you have funny and adorable videos or pictures of your pet you want to share? We want to see the best ones! Send them in to life@newsweek.com and they could appear on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Tom's Guide
3 hours ago
- Tom's Guide
I swapped the StairMaster for hill running — here's what it did for my mind and body
The StairMaster is a popular gym machine that offers a hefty lower-body workout. On those revolving steps, you build strength in your quads, glutes, and calves while challenging your cardio and burning calories. That's all fine and well until you get bored three minutes in, staring at the plain white gym wall in front of you, wishing you had downloaded something on Netflix to pass the time as you count down the remaining steps. There are certainly ways to spice up your StairMaster sessions; for example, my colleague Sam tried the 25-7-2 TikTok workout for a week. The challenge involves setting your StairMaster to level seven, stepping for 25 minutes, and completing the workout twice a week. But I'm a sunshine worshipper, and if I can work out outdoors instead of indoors, I will. So, while trying to figure out how I could get benefits similar to those offered by StairMaster, I decided to ditch the StairMaster and the gym altogether and take to my local hills to work out. Here's what happened. I felt a bit like a grandma saying 'technology is great, isn't it,' but it really did help when I started looking for good hill running spots. After moving to my new area, I used Strava's route maps (part of its premium features) and played around with filters like elevation and distance to find hilly routes other local runners were using. For my first session, I didn't follow a set plan. I just wanted to see how I handled the elevation. If you already know your local hills, you could turn them into a short workout, like a set of sprints with jog-back recoveries. It sounds a bit cliché, but I genuinely feel a rush when running up a steep hill, surrounded by greenery with even bigger hills looming in the background. Breathing in fresh air instead of the recycled, sweaty air from the gym is also a huge bonus. Hill running is undeniably hard, but being outdoors helps to distract you from how tough it is. Plus, it's easier to take walking breaks without messing around with machine settings. You can just ease off when you need to and get going again when you're ready. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. I know I'm lucky to live right at the foot of some scenic hills, and not everyone will have easy access to this. But you definitely don't need to live near mountains to give hill running a go. A steeper path in your local park can work just as well, and apps like Strava are great for spotting popular hill routes nearby. If you're heading off-road like I did, I'd highly recommend wearing a pair of the best trail running shoes for adding grip and stability on uneven ground. The Hoka Speedgoat 6 is built for rugged terrain, with grippy soles that keep you stable on uneven trails and a cushioned feel that helps soften steep climbs and descents. They're light, comfortable, and designed to handle hills with confidence. Just like the stairmaster, hill running really puts your glutes to work. It mainly activates the gluteus maximus, which plays a key role in hip extension and powering you forward as you climb. The steeper the gradient, the harder those muscles fire to keep you moving. I usually notice it the day after, not an overwhelming soreness, but a solid, satisfying ache that feels like progress. In short, hill running is a practical way to build glute strength using just your body and the terrain. Hill running is not just a tough workout but one with real benefits. A recent study published in the Journal of Sports Sciences looked at hill runners' fitness, body composition, and performance. It found that better aerobic capacity and lower body fat were linked to stronger hill running performance. The study also noted that hill running pushes you close to your maximum effort, which is a sign of an effective cardiovascular workout. However, it's important to note that another key takeaway from the study was that many hill runners might be burning more energy than they take in, so fueling properly is important if you increase your hill running sessions. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
Geek Wire
3 hours ago
- Geek Wire
Alaska Airlines grounds flights across U.S. due to IT outage
is GeekWire's editor, responsible for coordinating the newsroom, planning coverage, and editing stories. A native of Portland, Ore., and graduate of the University of Washington, he was previously a GeekWire staff reporter, covering beats including startups and sports technology. Follow him on LinkedIn or email taylor@
Newsweek
5 hours ago
- Newsweek
FDA Suspends Muscular Dystrophy Drug After 3 Patient Deaths
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The U.S. Food and Drug Administration (FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational gene therapy trials for limb girdle muscular dystrophy following three patient deaths potentially linked to the company's treatments. The agency announced the action on Friday, citing serious safety concerns and "unreasonable and significant risk" to study participants. The FDA also revoked the company's platform technology designation and requested Sarepta voluntarily halt shipments of its approved drug Elevidys, which the company refused to do. Newsweek reached out to Sarepta Therapeutics via email on Sunday after normal business hours for comment. Why It Matters This regulatory intervention represents a significant safety measure in the gene therapy field, affecting both ongoing clinical trials and an already approved treatment for Duchenne muscular dystrophy. The decision could impact treatment options for families dealing with these devastating muscle-wasting diseases. Duchenne muscular dystrophy is a rare and serious genetic condition that worsens over time, leading to weakness and wasting away of the body's muscles. What To Know The three deaths resulted from acute liver failure in patients treated with either Elevidys or investigational therapies using the same AAVrh74 viral vector technology. One fatality occurred during a clinical trial for limb girdle muscular dystrophy treatment. Elevidys is an adeno-associated virus vector-based gene therapy designed to deliver a gene that leads to production of a shortened protein that contains selected domains of the dystrophin protein present in normal muscle cells. The disease occurs due to a defective gene that results in abnormalities in, or absence of, dystrophin, a protein that helps keep the body's muscle cells intact. The drug received traditional approval for ambulatory DMD patients aged 4 and older on June 20, 2024, while maintaining accelerated approval for non-ambulatory patients since June 22, 2023. Under accelerated approval, companies must conduct confirmatory studies to verify clinical benefit. Given the new safety concerns, the FDA has notified Sarepta that the drug's indication should be restricted to ambulatory patients only. The FDA revoked the platform technology designation for Sarepta's AAVrh74 Platform Technology because the preliminary evidence is insufficient to demonstrate that the technology has the potential to be incorporated in multiple drugs without adverse safety effects. What People Are Saying FDA Commissioner Marty Makary, M.D., M.P.H.: "Today, we've shown that this FDA takes swift action when patient safety is at risk. We believe in access to drugs for unmet medical needs but are not afraid to take immediate action when a serious safety signal emerges." Dr. Vinay Prasad, Director of FDA's Center for Biologics Evaluation and Research: "Protecting patient safety is our highest priority, and the FDA will not allow products whose harms are greater than benefits. The FDA will halt any clinical trial of an investigational product if clinical trial participants would be exposed to an unreasonable and significant risk of illness or injury." FILE - The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, Tuesday, April 22, 2025. FILE - The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, Tuesday, April 22, 2025. AP Photo/Jose Luis Magana, File What Happens Next The FDA will continue investigating the risk of acute liver failure and other serious outcomes following gene therapies using Sarepta's AAVrh74 platform technology. The agency has committed to taking additional regulatory actions as needed to protect patients. For current Elevidys patients, the FDA is focusing its safety investigation on ambulatory patients while restricting the drug's use in non-ambulatory patients.
